Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly farletuzumab plus carboplatin and taxane in platinum-sensitive ovarian cancer first relapse
jRCT2080221321Phase 3
- Sponsor
- Eisai Co., Ltd.
- Start
- Nov 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) comparing Farletuzumab + carboplatin + taxane with Placebo + carboplatin + taxane (2 arms).
02
Drugs
farletuzumab
03
Conditions
epithelial ovarian cancer (EOC)primary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on jRCT2080221321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221321.